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Abstract  1 
Solid form screening to identify all solid forms of an API has become increasingly important 2 
in ensuring Quality by Design of pharmaceutical products and their manufacturing 3 
processes.  However, despite considerable enlargement of the range of techniques that 4 
have been shown capable of producing novel solid forms, it is possible that practically 5 
important forms may not be found in the short timescales currently allowed for solid form 6 
screening. Here, we report on the state-of-the-art use of computed crystal energy 7 
landscapes to complement pharmaceutical solid form screening. We illustrate how crystal 8 
energy landscapes can help establish a molecular level understanding of the crystallization 9 
behavior of APIs and enhance the ability of solid form screening to facilitate pharmaceutical 10 
development. 11 
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Glossary  20 
API: Active pharmaceutical ingredient 21 
Polymorphs: different crystal structures with the same chemical composition with the 22 
molecule(s) having a defined covalent bonding and stereochemistry.  Like many solid state 23 
forms which can form a continuum [7], the definition can vary, but herein racemic crystals 24 
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containing the API and its mirror image, and conglomerates of enantiopure structures 1 
containing just one hand, are considered as polymorphs.  Conformational polymorphs arise 2 
when the molecular conformation in each form differs significantly, such that the closest 3 
isolated molecule conformational energy minima are different [8]. Packing polymorphs have 4 
the same molecular conformation packed in different ways. 5 
Crystal form: general term for a single or multi-component crystalline solid. Crystal forms of 6 
a parent compound, salt or co-crystal that include the solvent of crystallization in the crystal 7 
structure are referred to as solvates and in the specific case where water is present, 8 
hydrates. Neat or non-solvated polymorphs refer to different crystal structures containing 9 
just the API with defined covalent bonding. The term solid forms includes both crystal and 10 
amorphous forms. 11 
Polymorph screen: a survey of crystallization conditions designed to identify solid forms of 12 
an API. Solvent-based screens are oftentimes tailored to the solubility properties of the API. 13 
A screen may encompass hundreds or even thousands of crystallization experiments. 14 
Concomitant crystallization: when two or more polymorphs are crystallized in the same 15 
experiment. 16 
Packing coefficient: the fraction of space in the crystal structure occupied by molecules or 17 
ions as defined by their van der Waals surfaces. The packing coefficient for spheres 18 
expressed as a percentage is 74%. 19 
Lattice energy: the energy required to separate the molecules in an infinite static perfect 20 
crystal lattice so that they are non-interacting and in their lowest energy conformation. This 21 
can be calculated at the electronic level, usually by periodic dispersion corrected density 22 
functional methods (DFT-D), or by splitting into inter and intramolecular contributions and 23 
using ab initio calculations on the molecule for the conformational energy and an accurate 24 
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model for the charge density which is used in modelling the intermolecular interactions in 1 
the crystal. The lattice energy can also be estimated by transferable force-fields, but this is 2 
rarely sufficiently accurate enough.  3 
Crystal Structure Prediction (CSP) methods were originally designed to predict the crystal 4 
structure as the most stable possibility. The prevalence of polymorphism means that these 5 
methods are now used to generate a (computed) crystal energy landscape, the set of 6 
structures which are thermodynamically plausible as polymorphs.  7 
  8 
6 
 
One of the first steps taken in developing a solid oral dosage form is to identify crystalline 1 
forms of the drug molecule, generally through some form of crystallization screening. 2 
Crystallization provides a means to purify and recover the drug substance coming out of the 3 
final step of the synthesis and to isolate the drug in a crystalline form that is suitable for 4 
downstream processing. Except in cases where an amorphous drug product is anticipated, 5 
crystallization is also used to define the material properties (e.g. stability, solubility) of the 6 
drug substance that will ensure consistency in the safety and efficacy profile of the drug 7 
product throughout its shelf life. Some compounds crystallize easily in solid forms that can 8 
be readily commercialized; however, all compounds are different and for some, the effort 9 
spent trying to crystallize the compound the first time, or in a form with suitable properties, 10 
is enormous. Other molecules crystallize in many different forms (including salts and co-11 
crystals), creating opportunities to design properties into the drug substance, but at the 12 
same time introducing challenges in deciding which form to develop, selectively crystallizing 13 
the preferred form at large scale and establishing control strategies around crystal form in 14 
the drug product.  15 
There is presently no way of knowing if a molecule will crystallize, let alone in how many 16 
forms or if any of those forms will be useful for ultimately delivering the drug from the 17 
dosage form to its site of action. Because solid form screening continues to be an exercise of 18 
trial and error, with no clear end point, the process is oftentimes extended well beyond the 19 
point of diminishing returns in order to provide reassurance that the relevant forms 20 
(polymorphs, hydrates) have been found. Under immense pressure to shorten development 21 
timelines and reduce costs, the pharmaceutical industry is keen on right-sizing the time and 22 
effort spent on finding commercially-viable solid forms. On the other hand, faced with the 23 
potential for a product failure should a new, more stable (less soluble) crystal form suddenly 24 
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appear in a marketed product, finding the most stable crystal form is non-negotiable. Crystal 1 
structure prediction (CSP), the process by which thermodynamically competitive crystal 2 
structures are calculated from a chemical diagram of the molecule [4,9], has the potential to 3 
change the game for the pharmaceutical industry. 4 
Solid form screening in the pharmaceutical industry 5 
Few active pharmaceutical ingredients (APIs) have only one crystalline phase with up to 6 
three in four compounds which are intensively screened displaying polymorphism [3]. Most 7 
are capable of forming multi-component forms such as salts, co-crystals and solvates, 8 
greatly expanding the potential solid form options for drug products [3,7,10]. The aim of 9 
experimental ‘polymorph’ screening is to produce the solid form landscape [11] relating all 10 
known solid forms of a parent compound, salt or co-crystal, and providing routes for their 11 
crystallization and interconversion as exemplified by the summaries in Figure 1. Although 12 
the implications of not finding the stable (generally preferred) form prior to product launch 13 
are well documented for ritonavir [12] and rotigotine [13], the conditions needed to 14 
nucleate any crystal form for the first time are not known a priori. Pharma has therefore 15 
largely embraced the trial and error approach to finding forms most notably with the 16 
introduction of high throughput screening in the early 2000’s. The idea was to expose 17 
compounds to hundreds, even thousands, of conditions in the hope of yielding new 18 
forms[14]. Initial investment in automated screening emphasized variations in solvent, 19 
supersaturation, cooling rates and other factors that would usually be controlled in a 20 
crystallization process. However, despite the huge research effort into developing 21 
experimental screening protocols, there are no “cookbook recipes” to find all relevant solid 22 
forms. The complexities of experimental screens are very dependent on the specific 23 
8 
 
molecule [15] and such automated systems working on small amounts of material have to 1 
be supplemented by bespoke manual screening [3,16].  2 
It has been suggested by McCrone [17] that the number of solid forms of a compound is 3 
proportional to the time and money spent investigating its crystallization. Industry whilst 4 
performing massive experimentation, with growth of contract research organizations to do 5 
screening work, needs to conclude on shorter timescales and direct experimentation 6 
efficiently. The plethora of possible experiments, which today extends beyond conventional 7 
methods to include heteronuclear screening using a bank of polymers [18], as well as 8 
crystallization in electric [19] and ultrasound [20] fields, in laser beams [21,22] and under 9 
confinement [23], makes it difficult to invoke a Quality by Design argument on a purely 10 
empirical approach. This has led to sustained interest in whether computational modeling 11 
can be used to reliably predict polymorphs, their properties and the experiments needed to 12 
produce the first sample [24].  13 
The development of computational Crystal Structure Prediction (CSP) 14 
The main application of the ability to predict crystal structures from a chemical diagram, i.e. 15 
prior to synthesis, has historically been seen as the design of new materials with desired 16 
physical properties, such as energetic materials or organic semi-conductors. A computer 17 
code that could predict the crystal structures of an organic molecule has to encapsulate and 18 
quantify the fundamental theory of what determines the crystal structures. The theoretical 19 
assumption in most programs is that the crystal structure is the most thermodynamically 20 
stable possibility. This, however, is too simplistic a theory to also predict metastable forms, 21 
i.e. polymorphism [25]. Polymorph prediction would require (Box 1) the generation of a set 22 
of putative crystal structures for the molecule, and scoring them for their probability of 23 
being observed. To date, successful CSP methods have ranked the crystal structures on their 24 
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relative thermodynamic stability as approximated by the relative lattice energy effectively 1 
corresponding to 0K. 2 
The ability to predict structures without experimental information has been periodically 3 
tested since 1999 [26-28] in Blind Tests sponsored by the Cambridge Crystallographic Data 4 
Centre, where those involved in developing CSP methods are invited to submit their 5 
predictions of unpublished structures. The papers described in the ensuing discussion show 6 
the development of the methods. Despite the limitations on the crystal structures used in 7 
the Blind Tests, they do reveal the progress and problems in the ability to predict organic 8 
crystal structures. One of the targets for the recent 6th Blind Test (Figure 2), molecule XXIII, 9 
has been shown to have five polymorphs and XXVI has also undergone commercial solid 10 
form screening. This industrial involvement is particularly valuable in reducing discussion as 11 
to whether some predicted structures are undiscovered polymorphs [29]. All of the 12 
experimentally known structures of the target systems were in fact generated by 13 
submissions in the 6th Blind Test, and many were ranked as being one of the most stable 14 
structures by one or more methods. However, no one method had all of the experimental 15 
structures as being more stable than unobserved alternatives. This is not surprising, as there 16 
are many challenges to computational chemistry involved in a CSP run [4,9] (see Box 1). The 17 
search space to be covered is immense, particularly for flexible molecules, where 18 
considering millions of putative structures may not be sufficient. For the known polymorphs 19 
of XXIII with two different conformations in the unit cell, the search space is so vast that 20 
most groups did not attempt to generate the Z’=2 structures. The Blind Test targets were 21 
restricted to those that could be reasonably approximated by the infinite perfect crystal 22 
used in the modeling, though disordered crystals are inevitable for some molecules [30].  23 
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The biggest challenge in CSP is to be able to rank the thermodynamic stability of the 1 
possible crystal structures accurately enough, given that the energy difference between 2 
known polymorphs is typically around a kJ/mol, though it can be up to 8 kJ/mol for 3 
conformational polymorphs [8]. The tiny energy differences between polymorphs can 4 
sometimes be measured by the heat of transformation or by the difference in their heats of 5 
fusion. The energy evaluation challenge is closely related to the problem of sufficient 6 
accuracy in force-fields or electronic structure calculations for predicting protein structures 7 
[31] or ligand binding energies in drug design [31,32]. Since the lattice energy of benzene 8 
has only recently been calculated to an absolute accuracy of less than 1 kJ/mol [33], CSP 9 
relies on effective cancellation of errors in the evaluation of the crystal energies. The more 10 
successful methods in the Blind Test either used electronic structure calculations on the 11 
isolated molecule conformations or on many hundreds of crystal structures. The Blind Tests 12 
have shown that worthwhile crystal energy evaluations have to be based on the electronic 13 
structure of the molecule and so scale very badly with the size of the molecule, the range of 14 
conformations that could appear in the solid state, and the number of independent 15 
molecules in the crystal structure (Box 1). The computational expense of the successful Blind 16 
Test submissions for the larger systems was measured in hundreds of thousands of CPU 17 
hours, corresponding to weeks to months of dedicated use of high performance computing 18 
clusters [6].  19 
To date, crystal structure prediction studies have been performed on many model drug 20 
compounds, and in cases such as aspirin, paracetamol, carbamazepine and 5-fluorouracil, 21 
have anticipated the discovery of new polymorphs [34]. After the 2nd Blind Test, two 22 
additional polymorphs of the sulfonamide (VI) were found, and the more accurate ranking 23 
by DFT-D showed that the known forms were the three lowest energy structures found [35] 24 
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in a search by the GRACE code [36]. Further examples of combined CSP and experimental 1 
studies leading to the few lowest energy structures being observed polymorphs include 2 
creatine [37] and 4-aminoquinaldine [38] and its most stable form, a polymorph of 3 
4-aminoquinaldine monohydrate, which proved very difficult to access experimentally for 4 
kinetic reasons [39]. This leads to the current research debate as to whether and why some 5 
structures may never be found, despite their apparent computed stability, or alternatively, 6 
whether an experiment can be devised to cause the first nucleation of any 7 
thermodynamically plausible structure [5,40].  8 
Academic work contrasting the known polymorphism of small organic molecules with the 9 
output of a CSP study has led to the concept of a computed crystal energy landscape [4]. 10 
This is the set of computer-generated crystal structures which are thermodynamically 11 
plausible as polymorphs. However, in most cases, there are considerably more structures on 12 
the crystal energy landscape than known polymorphs [5]. Some of these structures are 13 
artifacts of the approximations currently used in calculating the crystal energy landscape, 14 
particularly the neglect of temperature and hence the molecular motion within the crystals, 15 
which means that not all structures are free energy minima. Would an accurate crystal 16 
energy landscape at ambient temperature and pressure define the possible polymorphs 17 
relevant to industry [4,5]? The experience from small organic molecules shows that the 18 
computed crystal energy landscape has the potential for: 19 
 Confirming that the most stable crystal structure is known [37] 20 
 Predicting the structures of potential polymorphs, and from these structures 21 
suggesting possible crystallization strategies to find them  [39]  22 
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 Helping structurally characterize polymorphs from powder diffraction data[41], solid 1 
state NMR [42,43], or electron diffraction [44], in cases where a single crystal 2 
suitable for structure determination by crystallography cannot be obtained 3 
 Anticipating disorder in crystal structures [45], and hence allowing more confident 4 
separation of varying disorder from mixtures of polymorphs 5 
 Understanding or rationalizing crystallization behaviors [4,5], e.g. monomorphism v. 6 
polymorphism, solvate formation, etc. 7 
How computed crystal energy landscapes help define pharmaceutical solid form 8 
landscapes. 9 
Industrial pharmaceutical scientists have closely monitored the development of CSP 10 
methods and in particular, the CCDC Blind Tests. Reliable CSP would determine whether 11 
their screening had missed the most stable solid form and further screening was warranted. 12 
Alternatively, if the practically important forms had been found, resources would be saved 13 
by not unnecessarily prolonging the search for forms. When XX in the 2010 Blind Test 14 
(Figure 2) inspired two groups to algorithmic developments that successfully predicted its 15 
structure [46], it showed that CSP methods were starting to be able to tackle molecules 16 
approaching the size and complexity of some molecules in development. We review the 17 
subsequent published examples of CSP that have been done in conjunction with industrial 18 
polymorph screening to show that the value of adding this computational technique 19 
extends well beyond right-sizing solid form screens.  20 
As this review will show, the uses of crystal energy landscapes established from the 21 
experience with small organic molecules can equally well be applied to pharmaceutical 22 
molecules. The evaluation of CSP is particularly useful on pharmaceuticals because of the 23 
extent of polymorph screening that has usually been done. It also presents a greatn 24 
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excellent opportunity to look at crystallization issues of pharmaceuticals, how they play out 1 
in industry and what CSP can contribute. Given that there is no statistical evidence that 2 
increasing molecular size and flexibility significantly changes the tendency to polymorphism  3 
[3], what has the combination of experimental and computational (in silica and in silico) 4 
solid form screening of pharmaceuticals taught us beyond what has already been learned 5 
from small molecule model systems? Why should the pharmaceutical industry care? The 6 
following examples on some molecules towards the smaller range of those being developed 7 
in the pharmaceutical industry (specified in Figure 3) illustrate some of the diversity of solid 8 
state behaviors that challenge solid form development and highlight the potential of 9 
computed crystal energy landscapes to augment solid form screening and selection.   10 
Why do molecules from the same drug discovery program have very different 11 
crystallization behavior? 12 
It may seem counterintuitive that molecules similar enough to act at the same protein 13 
receptor can have dramatically different crystallization behavior. However, crystal 14 
structures are very sensitive to all types of intermolecular contacts surrounding the 15 
molecule and not just the functional groups that bind to the receptor [47]. Hence, molecules 16 
from the same drug discovery program can pose very different challenges when it comes to 17 
progressing solid forms in drug development. A CSP study highlighting the different 18 
challenges used two 5-HT2a agonists, LY2806920 (B5) and LY2624803 (DB7), both of which 19 
were under development for sleep disorders. B5 readily and reliably crystallizes into just one 20 
solid form containing the neutral molecule, whereas three neat polymorphs, two hydrates, 21 
three alcohol solvates and an amorphous phase are known for DB7 (Figure 1) [48]. The 22 
screening effort was roughly equivalent for B5 and DB7 with respect to the number of 23 
experiments, but since B5 crystallized so readily, it was very difficult to avoid memory of the 24 
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input materialminute molecular clusters (nuclei) of the starting form being carried over into 1 
thein crystallization experiments, whereas amorphous DB7 could be used. The reason for 2 
the difference in number of solid forms of B5 and DB7 was not a difference in the energy 3 
spectrum of the crystal energy landscape (Figure 1), but rather in the density and nature of 4 
the low energy structures. B5 could pack densely with itself, with most low energy 5 
structures having an internal hydrogen bond. In contrast, DB7 had no good way of packing 6 
densely with itself, with the packing coefficients of predicted low energy structures lying in 7 
the lower half of the commonly observed range (65-75%). The low energy structures for DB7 8 
mainly had intermolecular hydrogen bonds forming a range of motifs, showing that crystal 9 
packing can have a major effect on the potential hydrogen bonding. These examples follow 10 
the general rule observed for small molecules, that both the crystal structure and energy 11 
landscapes are very specific to the individual molecule, and even the smallest changes in the 12 
API will usually result in different crystal structures and probably crystallization behavior.  13 
The nature of the solid form landscape 14 
Solid form diversity, disorder and why mixtures of polymorphs sometimes cannot be avoided 15 
Despite the increasingly comprehensive exploration of crystallization conditions and 16 
development of advanced analytical tools to detect and characterize solid-state forms, two 17 
challenges in generating solid form landscapes remain: finding experimental conditions 18 
which will induce a crystal form to nucleate for the first time and identifying bonafide crystal 19 
forms amidst materials that are frequently poorly crystalline, disordered or mixtures of 20 
phases. In the CSP study of 5-HT2a agonist DB7, a metastable polymorph, Form III, could only 21 
be obtained in polycrystalline form by desolvating the zwitterionic dehydrate [49] (Figure 1). 22 
The question was raised as to whether sample to sample variability in the properties of 23 
Form III was due to concomitant crystallization of two closely related polymorphs. The 24 
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computed crystal energy landscape found a match to its powder diffraction pattern in two 1 
structures, differing only in the propionic acid conformation, allowing characterization of 2 
this solid form as a single polymorph with variable sidechain disorder ) [48]. In this instance, 3 
the combined use of experimental screening and CSP showed a disordered structure for 4 
Form III was inevitable, helping to clarify the number of forms produced by the solid form 5 
screening) [48].  6 
In contrast, olanzapine, marketed for the treatment of schizophrenia, generated a lot of 7 
work contesting patent claims of “novel” polymorphs by generic companies prior to its 8 
coming off patent in the USA in 2011. In many cases, the purported forms were known 9 
mixtures of the concomitantly crystallizing metastable polymorphs, Forms II and III. The 10 
structure of Form II was only determined in 2011, when a single crystal suitable for X-ray 11 
could be picked out from a sample of olanzapine that had failed to co-crystallize with 12 
nicotinamide [50]. A single crystal of Form III was not identified for X-ray structure analysis; 13 
however, the crystal energy landscape included a structure that was a sufficient match to 14 
the Form III powder pattern to show that it was a different stacking of the same molecular 15 
layers as Form II [51]. This structural model rationalizes why Forms II and III crystallize 16 
concomitantly, with it being practically impossible to generate phase pure samples. 17 
The problems of differentiation between different polymorphs and degrees of disorder, and 18 
the consequences for the quality control of crystal properties, is further exemplified by the 19 
case of tazofelone. The original screening of racemic tazofelone had produced two 20 
polymorphs [52], which were based on the same layer structure with different stackings in 21 
the third dimension. Revisiting this compound to obtain good thermodynamic data for 22 
calibrating the CSP study [53] unexpectedly produced an alternative stacking as a third 23 
polymorph. Of particular concern for ensuring quality control over material properties was 24 
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that the large single crystals of each polymorph varied in melting point. This triggered an 1 
unusually detailed examination of the raw diffraction data to reveal evidence of significant 2 
disorder. The crystal energy landscape had the most stable form as the global minimum, but 3 
showed that there were other ways of stacking the layers that were so close in energy, that 4 
stacking errors or different polymorphic domains (polytypes) even within single crystals 5 
were probably unavoidable.  6 
Determination of crystal structure when single crystals cannot be grown.  7 
The examples surveyed thus far show how crystal structures are sometimes needed in order 8 
to clarify experimental solid form landscapes. Structural information is also used to 9 
rationalize and understand crystallization behaviors, and as interest in emerging in silico 10 
approaches to drug product design continues to grow, structures will undoubtedly be 11 
necessary inputs to the modeling and prediction of solid-state properties well into the 12 
future. A further example of using CSP, this time in conjunction with a range of experimental 13 
techniques to determine the crystal structure, is illustrated for AZD8329, an 11-HSD1 14 
inhibitor investigated for use in the treatment of type 2 diabetes. AZD8329 showed 15 
significant polymorphismcrystallizes in at least four neat polymorphs, with Form 4, one of 16 
two forms considered to have superior properties for development, not having a crystal 17 
structure determination. The structure was proposed [54] by comparing the experimental 18 
proton solid state NMR spectrum with those calculated from CSP generated structures (Box 19 
1) with both the cis and trans amide conformations. The proposed structure of Form 4 with 20 
a cis amide was in excellent agreement with that independently determined from powder X-21 
ray diffraction, with the advantage of NMR spectroscopy having located the carboxylic acid 22 
proton position. 23 
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A related study attempted to use CSP to find structures for the anhydrous forms of the 1 
antibiotic levofloxacin, using the commercial program Polymorph Predictor [55]. In the end, 2 
a plausible model was proposed after using the crystal structures of six carboxylic acid salt 3 
and hydrate forms to choose six likely ππ stacked dimer structures, which were optimized 4 
by electronic structure methods and held rigid during the CSP search. This illustrates the use 5 
of a limited approximate form of CSP to extrapolate from a marked structural preference 6 
(“structural synthon”) seen in other solid state forms of the API.   7 
Why are some molecules prolific solvate formers?  8 
Many pharmaceuticals are prolific solvate formers, with sulphathiazole having over 100 9 
solvates reported [56]. This considerably complicates the solid form screening output. 10 
Pharmaceutical solvates with solvents that would never be allowed anywhere in a 11 
production process because of their toxicity, have to be considered in screening because 12 
desolvation [57] is a sufficiently productive method of finding new forms and may be the 13 
only route to a new polymorph. Conversely, all possible hydrates have to be extensively 14 
studied and characterized because of the impossibility of rigorously excluding water from 15 
the production processes. Solvates can include multiple solvents, sometimes in variable 16 
ratios, and the distinction between surface absorbed water, stoichiometric and non-17 
stoichiometric hydrates is both critical for process design and difficult to establish [49]. 18 
Labile solvates, where the solvent readily leaves the crystal when it is removed from the 19 
crystallizing solution are common. CSP generated structures with void spaces can be 20 
stabilized by the inclusion of solvent molecules [58]. The nature of this stabilization, the 21 
ease of removing the solvent, and ability of the molecule to rearrange into a dense 22 
unsolvated form is extremely dependent on the specific structure, but could suggest a route 23 
to a desirable high solubility, low density, and kinetically stable form. The extension of the 24 
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principles of CSP on inclusion compound frameworks and porous molecular cages [59] to 1 
pharmaceutical solids and solvates is yet in its infancy, as a quicker, more general route to 2 
predicting solvate formation [60,61]. For example, we need to progress beyond just 3 
attributing the formation of solvates and hydrates of DB7 and none for B5 to the inability of 4 
only DB7 to pack densely by itself (Figure 1).  5 
Olanzapine also illustrates how the inability of a molecule to pack well with itself can give 6 
rise to a multitude of solid forms, with over 60 being found in the screen [51]. Many of these 7 
had differing solvent mixtures between layers of olanzapine dimers, and the crystal energy 8 
landscape showed that these layers do not stack particularly well to form an unsolvated 9 
crystal. The separation of solvate motifs and polymorphs is more challenging for the Pfizer 10 
oncolytic axitinib (AG013736), which has 71 forms, including 5 neat polymorphs [57]. A very 11 
limited CSP study, using the commercial force-field based method Polymorph Predictor [62] 12 
concluded that only a carefully modified force-field was able to find the polymorphs within 13 
the top 500 structures generated with the appropriate conformation. A fuller search [63] 14 
using ab initio methods to find molecular conformations and energies and CrystalPredictor 15 
did find all the polymorphs (Box 1), but also showed that there are many alternative 16 
structures that were thermodynamically competitive. Considerable efforts had already gone 17 
into developing targeted screens [57] to circumvent the solvation issues associated with 18 
conventional screening methods for axitinib, so that the expense of further computational 19 
work would only be justified if a clear pathway to crystallizing further polymorphs could be 20 
proposed.  21 
Why we sometimes miss finding more stable forms 22 
Detecting potential problems with chiral resolution by crystallization 23 
19 
 
Crystallization is often seen as an ideal process for the separation of enantiomers required 1 
to satisfy regulatory demands that chiral drugs are administered in an optically pure form 2 
[64]. As such, screening and development are generally directed to just the active 3 
enantiomer. The dangers of this strategy are shown by LY156735, a melatonin agonist, in 4 
which two polymorphs are known, but the most stable form has only been obtained for the 5 
inactive S enantiomer. In fact, had crystallization studies not been performed on the inactive 6 
isomer, there would be no reason to believe that a more stable crystal form existed [65]. 7 
CSP would, however, have alerted to this possibility, with the crystal energy landscape 8 
having both enantiomorphs and the known racemic form within the top 9 structures, all 9 
within 1 kcal/mol of the unobserved most stable form (Box 1) [65].   10 
Chiral resolution by crystallization is, of course, only possible when the opposite enantiomer 11 
is rejected during crystal growth. For tazofelone, an unusual experiment of seeding a 12 
racemic melt with the enantiopure (R or S) crystal instead results in an isostructural solid 13 
solution [66], i.e. the enantiopure crystal structure can include a variable proportion of 14 
molecules of the other hand. This phenomenon can be explained by the computed crystal 15 
energy landscape [53] including isostructural racemic structures that are more stable than 16 
the enantiomorph, albeit metastable relative to the other known racemic polymorphs. Since 17 
a change in conformation of the molecule effectively has the same packing ability as a 18 
change in chirality, recrystallization of predominantly enantiopure tazofelone will absorb 19 
rather than exclude chiral impurities. 20 
Is the lack of observed polymorphs in a screen reliable? 21 
The failure of experimental solid form screens to produce more than one crystal form may 22 
be due to one form being much more stable or crystallizing much more rapidly than all 23 
others. In such cases, CSP can uniquely show whether monomorphism is a product of 24 
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thermodynamics or crystallization kinetics. An example where alternative crystal structures 1 
were calculated [67] to be only slightly less stable than the only readily crystallized form is 2 
GSK269984B. In this case, the hypothetical polymorphs had intermolecular hydrogen 3 
bonding compensating for adopting grossly different, higher energy conformations than the 4 
observed more stable, internally hydrogen bonded conformation [67]. Further screening, 5 
concentrating on solvents that would be likely to hydrogen bond to the API, produced some 6 
metastable solvates with the expected intermolecular hydrogen bonding, but the same 7 
gross conformation as in the neat form. Thus the question arises as to whether the fast 8 
crystallization of GSK269984B into its most stable form could be relied upon to prevent the 9 
crystallization of the alternative computer generated structures [67], given that solution 10 
NMR showed that a range of other conformations could exist in solution. In ritonavir, it was 11 
the small solution population of the higher energy conformation that was found in the most 12 
stable polymorph that rationalized its disastrous later appearance [68,69]. The key 13 
difference for GSK269984B is that the higher energy conformers are calculated to give 14 
metastable polymorphs. 15 
Crizotinib was developed by Pfizer for the treatment of forms of lung cancer, and extensive 16 
polymorph and hydrate screening similarly found only one crystalline form. A simple CSP 17 
search, based on just four rigid, carefully selected conformers and the five most common 18 
chiral space groups, showed that the known structure was significantly more stable than any 19 
other generated, rationalizing the lack of polymorphs [24]. That the known structure not 20 
only had the lowest energy conformation but also optimal intermolecular interactions was 21 
confirmed by a CCDC solid form informatics “healthcheck” [70]. It is unusual that there are 22 
no signs of alternative crystal forms in the screening and so the computational confirmation 23 
that there is no compromise between conformation and intermolecular packing in the 24 
21 
 
structure, and that it has a uniquely favourable packing defining all three dimensions, 1 
provides valuable reassurance.  2 
Suggesting experiments to find new polymorphs 3 
A polymorph that had been missed in extensive experimental screening of Roche’s CETP 4 
inhibitor, Dalcetrapib, has recently been found by crystallisation under pressure, an 5 
experiment suggested by the CSP study [71]. The crystal energy landscape had two 6 
structures very close in energy, but denser than the known stable form; which was the most 7 
stable structure of all those generated in the search depending on the DFT-D method used. 8 
The unknown structures were calculated to become more stable than the observed 9 
polymorph with a modest increase in pressure. Experiments recrystallizing Dalcetrapib, 10 
either from solution or the melt in a diamond anvil cell under modest pressure formed a 11 
new polymorph. This matched the predicted polymorph, except for disorder in the 12 
hydrocarbon tail, which could have been anticipated from the crystal energy landscape. The 13 
new form was metastable at ambient pressure, converting to the stable form over a few 14 
hours. This shows how CSP can suggest a route to a form missed by conventional screening 15 
on the basis of the properties of the computer generated structures. The new form and the 16 
disorder in the side chains may have implications for the mechanical behaviour of crystals of 17 
the most stable form if subjected to pressure during processing.  18 
Discussion 19 
What are the advantages of leveraging CSP in pharmaceutical development?   20 
In the few years in which we have been able to calculate realistic crystal energy landscapes 21 
for pharmaceuticals it has been established that Crystal Structure Prediction studies can 22 
significantly complement industrial solid form screening. Enhancing the experimentally 23 
known crystal structures with computer generated ones helps make the links between the 24 
22 
 
structures of the neat forms, solvates, co-crystals, salts and their polymorphs. Establishing 1 
whether there are alternative, very similar structures of comparable energy further gives an 2 
entrée into understanding the extent of the API’s solid state continuum [7] between perfect 3 
crystals and possible varying degrees of disorder that may be defined by the crystallization 4 
conditions. When used in conjunction with the cutting-edge experimental infrastructure 5 
that industry needs for less empirical formulation and process design [72], this can help 6 
define the diversity of the solid state, particularly when the boundaries are not clear cut, 7 
such as with non-stoichiometric solvates or where the proton position blurs the 8 
salt/co-crystal boundary [73].  9 
The main advantage of calculating an extensive crystal energy landscape is to show what 10 
types of crystal structures are thermodynamically competitive with the crystal forms that 11 
have already been found in screening. Are there structures which are sufficiently different 12 
from the known forms that serious consideration must be given to whether the range of 13 
screening experiments so far is sufficient? Or should additional experiments be undertaken, 14 
such as crystallization under pressure to target denser polymorphs as illustrated by 15 
Dalcetrapib [71]? Combining the experimental data with the crystal energy landscape 16 
develops a molecular level understanding of the crystallization behavior of a specific API. 17 
This allows the experimentalist to focus efforts on the polymorphs that matter, significantly 18 
reducing the experimental effort. 19 
What are the challenges in developing CSP as a complement to solid form screening? 20 
As the results of the 6th Blind Test show, there is a long way to go until realistic crystal 21 
energy landscapes can be routinely calculated for pharmaceutical molecules. The successes 22 
for the larger flexible molecules were limited to methods where specialists used hundreds 23 
of thousands of hours of computer time. Incorporating CSP into solid form screening early 24 
23 
 
enough to assist the search for solid forms will require that the crystal energy landscape can 1 
be calculated far more readily and quickly. We cannot just rely on the increase in computer 2 
speeds and the increasing availability of powerful computer clusters in the pharmaceutical 3 
industry. Algorithmic developments are on-going particularly to deal with flexibility in the 4 
generation of putative crystal structures, but this requires validation data [74] which the 5 
pharmaceutical industry is uniquely suited to provide as shown by the value of BMS-488043 6 
[75] for the development of CrystalPredictor [76]. The evaluation of the relative energies of 7 
the crystal structures by a hierarchy of increasingly more accurate models on a smaller 8 
number of structures has to push at the current boundaries of our ability to model lattice 9 
energies and describe the effects of temperature. Some state of the art methods were used 10 
in the 6th Blind Test, showing that we cannot yet usefully predict the energy differences 11 
between known polymorphs for pharmaceuticals. However, as shown by tazofelone, 12 
experimental investigations of the thermodynamics of polymorphs can reveal surprises. Real 13 
crystalline materials at ambient conditions can be dynamically or statically disordered and 14 
very different from the static perfect infinite crystals in the calculations. Insights into the 15 
differences can inform understanding the transformations and apparent stability or 16 
metastability of the forms. This helps tie together and rationalise the measurements of key 17 
solid state properties for development that may appear to contradict expected correlations 18 
in behaviour, as shown by the hydrates of DB7 [49].   19 
On the other hand, as the examples of levofloxacin and crizotinib show, cheaper, restricted 20 
search space CSP studies with lower accuracy energies can be very useful for specific 21 
purposes, such as suggesting or eliminating certain types of structures. However, it is 22 
important to fit the computer modelling to the question: there have been cases where CSP 23 
24 
 
studies have wrongly concluded that further polymorphs are unlikely through insufficient 1 
coverage of the possible range of crystal structures [77].  2 
Will polymorph prediction ever be a black-box computational tool? Fundamental 3 
understanding of crystallisation for flexible molecules  4 
Pharmaceuticals (c.f. Figure 3) cannot be assumed to have the same crystallisation 5 
behaviour as small, rigid molecules which can readily rearrange to the most stable form. The 6 
molecule may not be able to pack densely with itself, and may not be able to change 7 
conformation or hydrogen bonding sufficiently during crystallisation to readily achieve the 8 
most stable structure. Polymorphs formed as desolvated solvates, or by chemical 9 
transformation (such as proton exchange) once the molecules are already highly aggregated 10 
may be very long-lived but far more metastable than small molecule polymorphs. Can the 11 
most stable structure on the crystal energy landscape always be crystallised? There are 12 
molecules that prove extremely difficult to crystallise at all, and so in these cases the first 13 
form is likely to be the fastest to nucleate and grow, which is not necessarily the most 14 
stable. Recent work on both a crystallographic dataset of diastereomers and chiral-racemic 15 
pairs [78], and many real and CSP generated crystal structures of mandelic acids [40] both 16 
point to statistics of nucleation and growth causing the rarity of spontaneous resolution of 17 
enantiomers by crystallization, and raise the possibility that the most stable computer 18 
generated structure may be very unlikely to ever form. Some intensively studied, highly 19 
polymorphic molecules, such as the precursor of olanzapine known as ROY [79] for the red-20 
orange-yellow spectrum of its many polymorphs, or axitinib, have a crystal energy landscape 21 
[80], where there are a large number of many thermodynamically competitive but 22 
unobserved polymorphs. In other cases, there are a few specific structures to be targeted 23 
[65], such as the melatonin agonist, or classes to be considered, such as whether it is 24 
25 
 
possible to crystallise olanzapine without first forming the dimer found in all known forms 1 
[51], or GSK269984B in a totally different conformation [67].  2 
The art of going from a computationally predicted polymorph to designing a method of 3 
producing it is a real challenge to our developing understanding of organic nucleation and 4 
growth[81], and an active research area. There are general approaches, such as the 5 
application of pressure for denser structures, c.f. Dalcetrapib[71], or adapting solvent range 6 
to observe undiscovered polymorphs with very different hydrogen-bonding motifs [82]. 7 
More specifically, the use of isostructural seeds to find predicted structures that were 8 
missed by conventional screening has been demonstrated by success in finally crystallising a 9 
predicted co-crystal of caffeine with benzoic acid in four geographically diverse laboratories 10 
[83]. Such specific seeding to find polymorphs has also been shown by the generation [84] 11 
of polymorph V of carbamazepine by sublimation onto an isostructural crystal of 12 
dihydrocarbamazepine form II. Form IV of carbamazepine was also not found in automated 13 
solvent screening experiments despite being exposed to a huge range of crystallisation 14 
experiments in different solvent screens and in forming its dozens of co-crystals [85]. It was 15 
found by polymer heteronucleation [86]. If we could reliably predict polymorphs in the time 16 
it takes to screen for solid forms and understood crystallisation well enough to know how to 17 
go from a predicted polymorph to the experiment to find it, this would revolutionise solid 18 
form screening.  19 
For pharma, the question is whether all polymorphs which are practically important for solid 20 
form selection and process design are known sufficiently early in the development cycle, 21 
with further investigations for IP protection following later. In cases like crizotinib and 22 
GSK269984B, which correspond to traditional expectations of easy, reliable crystallisation 23 
into only one form, limited CSP and other healthchecks can provide the confidence to stop 24 
26 
 
screening and develop with the knowledge of the competitive structures that can be 1 
avoided (or searched more extensively for when product protection is an issue). When the 2 
CSP and screening show that there are other competitive forms, then the calculations can 3 
help structurally characterise experimental forms and inform about the range of possible 4 
undiscovered polymorphs, guiding decisions on whether and where to direct further 5 
experimental work. There is still a long way to go until we understand the kinetics of 6 
nucleation and growth sufficiently to be able to proceed from calculating a crystal energy 7 
landscape to a reliable method of polymorph prediction.   8 
Conclusion  9 
We have reviewed a dozen case studies that have been published in the last few years since 10 
it has become possible to perform CSP studies on small drug molecules which are being 11 
screened in industry. The studies which that augment solid form screening show very 12 
different behavior, from reliable crystallization into one solid form through to extensive 13 
polymorphism, and the need for CSP to characterize forms and help rationalize and cope 14 
with problematic crystallization behavior such as disorder. Each case is unique, just as every 15 
polymorph screen is unique and the optimal design of each drug product is unique. The 16 
computed crystal energy landscapes can provide the early warnings of where the issues in 17 
further development of the drug product and processing will lie. Molecular-level insights will 18 
help to us to reduce the experimental burden showing us the steps to the promised goal. 19 
Computational crystal structure prediction is en route towards delivering on the two most 20 
important industrial promises: lead experimentalists to new crystal forms and help decide 21 
when it is safe to stop screening. As the ability to predict key properties, such as solubility or 22 
mechanical properties from the crystal structure improves, the crystal energy landscape will 23 
27 
 
show the range of property variation possible, and perhaps lead to deliberately targeting 1 
and developing metastable or multi-component forms for their improved properties.  2 
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Figure 1 Contrasting summaries of experimental solid form screening and CSP results for 1 
LY2806920 “B5” and LY2624803 “DB7” [48],  whose molecular structures are given in Figure 2 
3. Left, the solid forms of the molecules and their interrelationships; right, the energies and 3 
packing efficiencies of the computer generated structures, with every symbol denoting a 4 
computer generated structure that is mechanically stable, according to the hydrogen 5 
bonding motif in graph-set notation [89].  6 
 7 
 
 
XX [2010 Blind Test] 
 
  
 
XXII 
 
XXIV salt hydrate 
 
XXVI largest so far in Blind 
Tests 
 
XXIII, 5 polymorphs, C and E are Z’=2 
 
XXV co-crystal 
  
Figure 2  The molecules whose crystal structures have been used in the Cambridge 8 
Crystallographic Data Centre’s  Blind Tests of crystal structure prediction (top, molecule XX 9 
from 5th test in 2010 [28]; rest, molecules from the 6th test in 2015). Participants were 10 
33 
 
invited to submit lists of 100 structures and success was judged as having the experimental 1 
structures within these lists. Full analysis of the ranking of the structures within each 2 
submission will be published shortly [6].  3 
 4 
 5 
  
 
LY2806920 “B5” 
1 polymorph [48] 
LY2624803 “DB7” 
3 polymorphs, 5 solvates[48] 
Olanzapine 
3 polymorphs, 56 solvates [51] 
 
 
 
AZD8329 
4 polymorphs, 3 solvates [54] 
Levofloxacin 
1 polymorph, 2 hydrates [55] 
Tazofelone 
3 racemic polymorphs, 1 
enantiomorph, solid solution [53] 
   
Axitinib 
5 polymorphs, 66 solvates [57] 
GSK269984B 
1 polymorph, 4-6 solvates 
[67] 
LY156735 
3 polymorphs [65] 
   
Crizotinib 
1 polymorph[24] 
Dalcetrapib 
3 polymorphs [71] 
BMS-488043 
2 polymorphs [76] 
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Figure 3 Pharmaceuticals with combined experimental and computational solid form 1 
screening.  2 
